Documents

Filter documents Clear search

pdf icon

FSRH CEU Statement on Nexplanon® Insertion Site 15 January 2020

File size: 327kb | Date: 15 January 2020 | Clinical Statements - PDF

This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD (manufacturer of Nexplanon®) to healthcare professionals in the UK about updated guidance regarding the recommended Nexplanon® insertion site.

pdf icon

FSRH CEU recommendation on extended use of the etonogestrel implant and 52mg levonorgestrel-releasing intrauterine system during COVID restrictions

File size: 396kb | Date: 20 March 2020 | Clinical Statements - PDF

At present, to reduce risk of coronavirus transmission, non-essential face-to-face contact with healthcare providers is being minimised where possible. Replacement procedures for long-acting reversible contraceptive (LARC) devices that have recently expired are non-essential. This FSRH CEU statement provides recommendation on extended use of the etonogestrel implant and 52mg levonorgestrel-releasing intrauterine system during COVID restrictions.

pdf icon

FSRH CEU clinical advice to support provision of effective contraception during the COVID-19 outbreak

File size: 402kb | Date: 20 March 2020 | Clinical Statements - PDF

During Covid19-related restriction in face-to-face contact with healthcare professionals, FSRH CEU offers the following clinical advice to support ongoing provision of effective contraception. Provision of effective contraception (this may be a bridging method in the short term) and emergency contraception are considered priority services.

pdf icon

FSRH CEU Statement: Contraception and Weight Gain (August 2019)

File size: 206kb | Date: 12 August 2019 | Clinical Statements - PDF

This statement reviews and summarises the available evidence regarding the effect of contraception on weight. Looking at each method individually, the FSRH CEU advises clinicians regarding proven and theoretical associations between contraceptive options and weight/BMI.

pdf icon

FSRH CEU Response to published study: Maternal use of hormonal contraception and risk of childhood leukemia: a nationwide, populate-based cohort study (September 2018)

File size: 320kb | Date: 1 September 2018 | Clinical Statements - PDF

A Danish database study suggests that children born to women who have used hormonal contraception (HC) in the three months prior to conception or in early pregnancy are at increased risk of developing childhood non-lymphoid leukaemia compared with children whose mothers have never used HC. The FSRH CEU provides a critical appraisal of the study in this statement.

pdf icon

FSRH CEU Statement: Contraception for Women with Eating Disorders (May 2018)

File size: 366kb | Date: 1 May 2018 | Clinical Statements - PDF

Sexually active women of reproductive age with eating disorders require effective contraception despite the fact that amenorrhoea and anovulation are common in this population. This statement provides clinicians with a resource for best helping women with eating disorders choose the most appropriate and acceptable contraception for them. Download and save the document here.

pdf icon

FSRH CEU Statement to published systematic review: The relationship between progestin hormonal contraception and depression: a systematic review (March 2018)

File size: 127kb | Date: 1 March 2018 | Clinical Statements - PDF

Much recent media attention has been given to the subject of a potential association between hormonal contraception and depression. The FSRH CEU monitors and reports relevant emerging evidence. A new systematic review published in Contraception examines the existing evidence relating to risk of depression associated with use of progestogen-only contraception (POC).1 The authors of the review conclude that the bulk of the evidence does not support an association between use of POC and depression based on validated measures. Meta-analysis was not possible due to the heterogeneity of studies.

pdf icon

FSRH CEU response to European Medicines Agency recommendations regarding use of ulipristal acetate for management of uterine fibroids (February 2018)

File size: 225kb | Date: 1 February 2018 | Clinical Statements - PDF

The European Medicines Agency (EMA) is currently reviewing the safety of use of Esmya® (ulipristal acetate) for management of uterine fibroids. This review follows reports of a very small number of cases worldwide of serious liver injury in women using Esmya. Until the review process is complete, temporary restrictions have been placed on commencing treatment with Esmya and guidelines for monitoring liver function in women already taking Esmya have been introduced. The EMA recommendations are available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/02/news_detail_002902.jsp&mid=WC0b01ac058004d5c1